Biolidics (SGX:8YY) FCF Margin % : 120.53% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Biolidics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biolidics's Free Cash Flow for the three months ended in Dec. 2024 was S$0.86 Mil. Biolidics's Revenue for the three months ended in Dec. 2024 was S$0.71 Mil. Therefore, Biolidics's FCF Margin % for the quarter that ended in Dec. 2024 was 120.53%.

As of today, Biolidics's current FCF Yield % is -2.03%.

The historical rank and industry rank for Biolidics's FCF Margin % or its related term are showing as below:

SGX:8YY' s FCF Margin % Range Over the Past 10 Years
Min: -709.75 Med: -228.24 Max: -32.33
Current: -87.04

During the past 10 years, the highest FCF Margin % of Biolidics was -32.33%. The lowest was -709.75%. And the median was -228.24%.

SGX:8YY's FCF Margin % is ranked worse than
83.41% of 211 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.33 vs SGX:8YY: -87.04

Biolidics FCF Margin % Historical Data

The historical data trend for Biolidics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolidics FCF Margin % Chart

Biolidics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-32.33

-224.81

-126.84

-709.75

-88.14

Biolidics Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-555.17	-1,539.02	1,230.00	-7,713.33	120.53

Competitive Comparison of Biolidics's FCF Margin %

For the Diagnostics & Research subindustry, Biolidics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biolidics's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biolidics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Biolidics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Biolidics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Biolidics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-0.691	/	0.784
	=	-88.14 %

Biolidics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	0.857	/	0.711
	=	120.53 %

Biolidics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Biolidics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biolidics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biolidics Ltd (SGX:8YY) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Howard Road, No. 11-09 Novelty BizCentre, Singapore, SGP, 369585

Website

https://www.biolidics.com

Biolidics Ltd is engaged in technology development, technology transfer, marketing, sale and distribution of biomedical technology, life, and medicine science-related products and services, and investment holding. The company's business segments are; Cancer, Infectious diseases, Laboratory services, and Corporate. The majority of the company's revenue is generated from the laboratory services segment which involves the business, operation, and provision of laboratory services to customers. Its operations are spread across Singapore, Japan, China, Europe, the United States, Hong Kong, the Philippines, Indonesia, and Others.

Biolidics Headlines

No Headlines